Related Experiment Videos
Magnesium in cardiac arrest (the magic trial)
D M Fatovich1, D A Prentice, G J Dobb
1Department of Emergency Medicine, Royal Perth Hospital, WA, Australia.
Insights
High-dose magnesium did not improve survival rates for out-of-hospital cardiac arrest (OHCA) patients in a randomized trial. Early defibrillation remains critical for ventricular fibrillation (VF) survival.
Area of Science:
- Emergency Medicine
- Cardiology
- Clinical Trials
Background:
- Out-of-hospital cardiac arrest (OHCA) carries a poor prognosis.
- Emerging evidence suggested high-dose magnesium might enhance survival rates.
- The emergency department (ED) is a critical setting for initial OHCA management.
Purpose of the Study:
- To evaluate the efficacy of high-dose magnesium sulfate (MgSO4) as a first-line therapy for OHCA of cardiac origin.
- To compare survival outcomes between patients receiving magnesium and placebo during advanced cardiac life support (ACLS).
Main Methods:
- A prospective, randomized, double-blind, placebo-controlled trial was conducted.
- 67 OHCA patients received either 5g MgSO4 or a placebo intravenously.
- Outcomes included ECG rhythm, return of spontaneous circulation (ROSC), and survival at various stages.
Main Results:
- No significant differences in ECG rhythm, ROSC, or survival to ED discharge between magnesium and placebo groups.
- One patient in the magnesium group survived to hospital discharge; none in the placebo group survived.
- More witnessed arrests occurred in the magnesium group (35% vs 11%).
Conclusions:
- High-dose magnesium as first-line therapy for OHCA did not significantly improve survival.
- Early defibrillation is the most crucial intervention for ventricular fibrillation (VF).
- Further research is needed to clarify magnesium's role in cardiac and cerebral resuscitation.
Abstract:
The prognosis of out of hospital cardiac arrest (OHCA) is dismal. Recent reports indicate that high dose magnesium may improve survival. A prospective randomized double blind placebo controlled trial was conducted at the emergency department (ED) of Royal Perth Hospital, a University teaching hospital. Patients with OHCA of cardiac origin received either 5 g MgSO4 or placebo as first line drug therapy. The remainder of their management was standard advanced cardiac life support (ACLS). Study endpoints were: (1) ECG rhythm 2 min after the trial drug; (2) return of spontaneous circulation; (3) survival to leave the ED; (4) survival to leave intensive care; and (5) survival to hospital discharge. Of 67 patients enrolled, 31 received magnesium and 36 placebo. There were no significant differences between groups for all criteria, except that there were significantly more arrests witnessed after arrival of EMS personnel in the magnesium group (11 or 35% vs 4 or 11%). Return of spontaneous circulation occurred in seven (23%) patients receiving magnesium and eight (22%) placebo. Four patients in each group survived to leave the ED and one from the magnesium group survived to hospital discharge. There were no survivors in the placebo group. In this study, the use of high dose magnesium as first line drug therapy for OHCA was not associated with a significantly improved survival. Early defibrillation remains the single most important treatment for ventricular fibrillation (VF). Further studies are required to evaluate the role of magnesium in cardiac and cerebral resuscitation.